Dr. Baynes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 East 29th Street
New York, NY 10016
Education & Training
University of the WitwatersrandClass of 1978
Certifications & Licensure
KS State Medical License 1989 - 2019
MO State Medical License 1995 - 2019
Clinical Trials
- Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 1997 Jun 01
Publications & Presentations
PubMed
- 21 citationsKRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.Roy D Baynes, Jennifer Gansert
American Journal of Therapeutics. 2009-11-01 - 25 citationsEarly intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease.Edward Peres, Polly E Kintzel, Roger Dansey, Roy D. Baynes, Muneer H. Abidi
Blood Coagulation & Fibrinolysis. 2008-04-01
Press Mentions
Merck’s KEYTRUDA® (Pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients with Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 ExpressionMarch 17th, 2022- Merck’s Keytruda Reduced Risk of Disease Recurrence or Death in Early Lung Cancer Patients by 24%March 17th, 2022
- Pivotal Phase 3 Data for KEYTRUDA® (Pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of MedicineFebruary 10th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
